SYBX - Synlogic Inc logo

SYBX

Synlogic Inc

Rev โ€”top 1%10Y
Hold

Synlogic, Inc. develops synthetic biotic medicines targeting rare genetic diseases like Urea Cycle Disorder and Phenylketonuria, utilizing a proprietary synthetic biology platform to advance its clinical-stage drug pipeline.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago โ†’$3today

Score Overview

1 Year
Score
Net Growth95.70%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.9
Net Growth98.22%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth95.98%
Net Trend30%
Net Income Consistency
Rev Growthโ€”
Rev Trend50%
Revenue Consistency
All Time
Scoreโ€”
Net Growth95.98%
Net Trend30%
Net Income Consistency
Rev Growthโ€”
Rev Trend50%
Revenue Consistency

See the full market ranking โ†’

Synlogic Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 545K to $ 0.00 and net income went from -$ 56M to -$ 1M. Revenue increased in 2 of those 5 years; net income in 3.

Synlogic Inc currently holds a 5-year HDB Score of 4.9 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-11
$ 1.18โ€”
1 Year2025-08-12
$ 1.46-19.18%
5 Years2021-08-12
$ 43.05-97.26%
10 Years2016-08-12
$ 441.00-99.73%
All Time2015-10-01
$ 740.25-99.84%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 0.00-$ 1M$ 14M
2024$ 8K-$ 23M$ 18M
2023$ 3M-$ 57M$ 47M
2022$ 1M-$ 66M$ 77M
2021$ 1M-$ 58M$ 128M
2020$ 545K-$ 56M$ 100M
2019$ 2M-$ 48M$ 119M
2018$ 2M-$ 48M$ 122M
2017$ 2M-$ 40M$ 87M
2016$ 444K-$ 26M$ 60M
IPO2015$ 0.00-$ 24M$ 89M

Explore beyond SYBX

You're looking at Synlogic Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies